News


All series


All News

GEN-1 immunotherapy demonstrated dose-dependent efficacy results in newly diagnosed patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer when treated in combination with the standard of care, according to results from the OVATION 2 study. Based on positive data in the phase I portion, the study is moving on to phase II with enrollment expected to begin in the second half of the year.

Treatment with SGX301 led to statistically significant responses in patients with cutaneous T-cell lymphoma, according to preliminary top-line results from the pivotal phase III FLASH trial released by Soligenix.

The FDA has issued a guidance regarding clinical trials during the Coronavirus disease 2019 pandemic in recognition of the challenges that may impact standard clinical trial procedures. The guidance acts as a set of recommendations to maintain the safety of patients enrolled onto trials and the trial’s integrity. 

Nelipepimut-S in combination with granulocyte-macrophage colony-stimulating factor demonstrated doubling of the difference in the increase in antigen-specific CD8 cytotoxic T-lymphocytes in patients with ductal carcinoma in situ of the breast who were HLA-A2-positive or A3-positive, express HER2 at immunohistochemistry1+, 2+, or 3+ levels, and are pre- or post-menopausal, according to preliminary results from the phase II VADIS study.

As business slows down in most sectors worldwide due to the spread of coronavirus disease 2019 (COVID-19), the biopharmaceutical industry is doubling its efforts in order to develop life-saving vaccines and diagnostic tools for use by clinicians across medical specialties. Swift actions by the FDA and other public health organizations are being taken to ensure the health care industry has the tools it needs to care for patients who may be affected by the virus.

The addition of tremelimumab to frontline durvalumab and the standard of care, platinum-based chemotherapy, did not demonstrate a statistically significant improvement in overall survival in patients with extensive-stage small cell lung cancer, missing the co-primary end point of the phase III CASPIAN trial, according to high-level results from the final analysis of the trial.

In an interview with Targeted Oncology, Carl Morrison, MD, DVM, senior vice president Roswell Park Comprehensive Cancer Center, discussed the rationale for evaluating the Ion Torrent-based approach to predicting response to immunotherapy. He highlighted the importance of this in the clinical setting and advances are necessary to further validate this as a biomarker of response.

From 2001 to 2017, the cancer death rates continued to decline in the United States, and these decreases were observed in all major racial and ethnic groups, as well as in males, females, adolescents, young adults, and children. However, the rates of cancer incidence for all cancers slightly increased in females from 2012 to 2016, according to the Annual Report to the Nation on the Status of Cancer, which was published in&nbsp;Cancer.<sup>&nbsp;</sup>

Vemurafenib monotherapy is an effective treatment for patients with&nbsp;BRAF&nbsp;V600-mutated non&ndash;small cell lung cancer,&nbsp;according to results from the phase II AcSe vemurafenib trial&nbsp;II study published in the&nbsp;Annals of Oncology.

African American males with prostate cancer may fare better in terms of overall survival than Caucasian males, according to the results of a pooled analysis of phase III data. The data were obtained through the PROCEED registry, which includes over 1900 patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T, created at the recommendation of the FDA.

Patients with metastatic hormone-sensitive prostate cancer with a luminal B tumor are associated with better outcomes with the addition of docetaxel chemotherapy to androgen deprivation therapy compared with androgen deprivation therapy alone. In a correlative study presented at the 2020 Genitourinary Cancers Sumposium, investigators also determined that the basal tumor subtype did not experience as much of a survival benefit with the addition of docetaxel to androgen deprivation therapy.

The FDA has granted a Fast Track designation for the evaluation of balstilimab in combination with zalifrelimab for the treatment of patients with relapsed or refractory metastatic cervical cancer, according to a press release from Agenus, Inc., the developer of balstilimab. Comprehensive data supporting the potential of the combination served as the basis for the designation.

The largest prospective dataset in previously untreated diffuse large B-cell lymphoma revealed the molecular heterogeneity of diffuse large B-cell lymphoma with potential treatment targets harbored by the cell-of-origin subtypes, based on data from a phase III GOYA study.&nbsp;<br /> &nbsp;